A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Trial Profile

A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Rabusertib (Primary) ; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 27 Jun 2016 Results published in the Investigational New Drugs
    • 08 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 May 2014 Planned End Date changed from 1 Apr 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top